Our data indicate that BH3 mimetics of A-1210477 plus ABT-263 inhibits the activation of DRP-1, and genetic downregulation or pharmacological inhibition of DRP-1 further enhances the combination-induced cytotoxicity in melanoma (Supplementary Figure 7 and Fig. 8). Here, DNM1L is linked to melanoma.